What is HC Wainwright’s Estimate for Arvinas Q3 Earnings?

Arvinas, Inc. (NASDAQ:ARVN) – Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Arvinas in a note issued to investors on Wednesday, February 12th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.54) per share for the quarter. HC Wainwright has a “Buy” rating and a $87.00 price objective on the stock. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. HC Wainwright also issued estimates for Arvinas’ FY2025 earnings at ($2.13) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($2.54) EPS and FY2028 earnings at $2.77 EPS.

A number of other equities analysts also recently commented on the stock. Stephens started coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. BTIG Research started coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Barclays dropped their target price on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. BMO Capital Markets restated an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Finally, Guggenheim restated a “buy” rating and issued a $57.00 target price on shares of Arvinas in a research note on Wednesday, February 12th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $60.00.

Arvinas Price Performance

Shares of ARVN stock opened at $18.63 on Monday. The company has a market capitalization of $1.28 billion, a P/E ratio of -3.99 and a beta of 1.88. The company’s 50-day simple moving average is $18.63 and its two-hundred day simple moving average is $23.05. Arvinas has a one year low of $16.61 and a one year high of $51.99.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same quarter in the previous year, the company posted ($2.53) earnings per share.

Institutional Investors Weigh In On Arvinas

Hedge funds and other institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in Arvinas during the third quarter valued at approximately $39,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Arvinas by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after acquiring an additional 440 shares during the last quarter. KBC Group NV lifted its position in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after acquiring an additional 1,255 shares during the last quarter. Quantbot Technologies LP lifted its position in Arvinas by 147.3% during the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its position in Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after acquiring an additional 1,798 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.